The clinical effect of nicorandil on perioperative myocardial protection in patients undergoing elective PCI: A Systematic Review and Meta-Analysis.
Many scholars have studied the effect of nicorandil on perioperative myocardial protection in patients undergoing elective percutaneous coronary intervention (PCI), but results are inconsistent. Therefore, we performed this meta-analysis. Finally, 16 articles, including 1616 patients, were included into this meta-analysis. Meta-analysis results showed that: (1) Nicorandil can reduce the level of CK-MB after PCI, including at 6 hours, 12 hours, 18 hours and 24 hours. (2) Nicorandil can reduce the level of TnT after PCI, including at 6 hours, 12 hours, 18 hours and 24 hours. (3) Nicorandil can reduce the incidence of adverse reactions after PCI. (4) Nicorandil cannot reduce the level of MVP after PCI, including at 12 hours and 24 hours. (5) Subgroup analysis showed that nicorandil can reduce CK-MB and TnT level at 24 hours after PCI for Chinese's population (P < 0.05), but can not reduce CK-MB and TnT level at 24 hours after PCI for non Chinese's population (P > 0.05). Our meta-analysis indicate that nicorandil can reduce myocardial injury and reduce the incidence of adverse reaction caused by PCI for Chinese's population, but is not obvious for non Chinese's population. However, this conclusion still needs to be confirmed in the future.
Department of cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular institue, Nanning, Guangxi, 530021, China.
Ziliang
Z
Ye
Department of cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular institue, Nanning, Guangxi, 530021, China.
Qiang
Q
Su
Department of cardiology, The First Affiliated Hospital of Guangxi Medical University, Guangxi Cardiovascular institue, Nanning, Guangxi, 530021, China.
Lang
L
Li
D015415:Biomarkers; D002316:Cardiotonic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017558:Elective Surgical Procedures; D006801:Humans; D020108:Nicorandil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017063:Outcome Assessment, Health Care; D062645:Percutaneous Coronary Intervention / Q000009:adverse effects; D019990:Perioperative Care; D017594:Publication Bias; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D015415:Biomarkers; D002316:Cardiotonic Agents; D014665:Vasodilator Agents; D020108:Nicorandil